Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S L Parsons

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|May 9, 2013
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancerA Khanna, A M Reece-Smith, M Cunnell, et al.
British Journal of Cancer|December 4, 1998
Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancyS L Parsons, S A Watson, H M Collins, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 21, 2012
A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib eraA M Reece-Smith, P MacGoey, M A Shah, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 16, 2014
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancerB H L Tan, K Brammer, N Randhawa, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|March 12, 2014
Analysis of lymphatic and blood vessel invasion biomarkers in T1 esophagogastric adenocarcinomas for improved patient prognosticationC Perry, I Soomro, P Kaye, et al.
British Journal of Cancer|May 13, 2010
Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapyK R Fareed, A Al-Attar, I N Soomro, et al.
Journal of Surgical Oncology|June 8, 2012
MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomasA M Reece-Smith, S Saha, M L Cunnell, et al.
The British Journal of Surgery|September 26, 2017
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinomaF Noble, M A Lloyd, R Turkington, et al.
Annals of the Royal College of Surgeons of England|May 3, 2017
Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinomaA M Reece-Smith, J H Saunders, I N Soomro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2012
Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis aloneP Wimberger, H Gilet, A-K Gonschior, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|May 9, 2013
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancerA Khanna, A M Reece-Smith, M Cunnell, et al.
British Journal of Cancer|December 4, 1998
Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancyS L Parsons, S A Watson, H M Collins, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 21, 2012
A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib eraA M Reece-Smith, P MacGoey, M A Shah, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 16, 2014
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancerB H L Tan, K Brammer, N Randhawa, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|March 12, 2014
Analysis of lymphatic and blood vessel invasion biomarkers in T1 esophagogastric adenocarcinomas for improved patient prognosticationC Perry, I Soomro, P Kaye, et al.
British Journal of Cancer|May 13, 2010
Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapyK R Fareed, A Al-Attar, I N Soomro, et al.
Journal of Surgical Oncology|June 8, 2012
MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomasA M Reece-Smith, S Saha, M L Cunnell, et al.
The British Journal of Surgery|September 26, 2017
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinomaF Noble, M A Lloyd, R Turkington, et al.
Annals of the Royal College of Surgeons of England|May 3, 2017
Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinomaA M Reece-Smith, J H Saunders, I N Soomro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2012
Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis aloneP Wimberger, H Gilet, A-K Gonschior, et al.
Pageof 4